Skip Navigation

Neuro-Oncology 2006 8(3):227-233; doi:10.1215/15228517-2006-007
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Navalitloha, Y.
Right arrow Articles by Groothuis, D. R.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Navalitloha, Y.
Right arrow Articles by Groothuis, D. R.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Society for Neuro-Oncology

Therapeutic implications of tumor interstitial fluid pressure in subcutaneous RG-2 tumors1

Yot Navalitloha, Erica S. Schwartz, Elizabeth N. Groothuis, Cathleen V. Allen, Robert M. Levy and Dennis R. Groothuis2

Department of Neurology, Northwestern University Medical School, Evanston Northwestern Healthcare, Evanston, IL 60201, and Northwestern University Institute for Neuroscience, Northwestern University, Evanston, IL 60208 (Y.N., E.S.S., E.N.G., C.V.A., R.M.L., D.R.G.); and Department of Neurosurgery, Northwestern University Medical School, Chicago, IL 60210 (R.M.L.); USA

2 Address correspondence to Dennis R. Groothuis, M.D., Department of Neurology, Evanston Hospital, 2650 Ridge Avenue, Evanston, IL 60201 (drgroothuis{at}northwestern.edu).


   Abstract

Increased interstitial fluid pressure (IFP) in brain tumors results in rapid removal of drugs from tumor extracellular space. We studied the effects of dexamethasone and hypothermia on IFP in s.c. RG-2 rat gliomas, because they could potentially be useful as means of maintaining drug concentrations in human brain tumors. We used dexamethasone, external hypothermia, combined dexamethasone and hypothermia, and infusions of room temperature saline versus chilled saline. We measured tumor IFP and efflux half-time of 14C-sucrose from tumors. In untreated s.c. tumors, IFP was 9.1 ± 2.1 mmHg, tumor temperature was 33.7°C ± 0.7°C, and efflux half-time was 7.3 ± 0.7 min. Externally induced hypothermia decreased tumor temperature to 8.9°C ± 2.9°C, tumor IFP decreased to 3.2 ± 1.1 mmHg, and efflux half-time increased to 13.5 min. Dexamethasone decreased IFP to 2.4 ± 1.0 mmHg and increased efflux half-time to 15.4 min. Combined hypothermia and dexamethasone further increased the efflux half-time to 17.6 min. We tried to lower the tumor temperature by chilling the infusion solution, but at an infusion rate of 48 µl/min, the efflux rate was the same for room temperature saline and 15°C saline. The efflux rate was increased in both infusion groups, which suggests that efflux due to tumor IFP and that of the infusate were additive. Since lowering tumor IFP decreases efflux from brain tumors, it provides a means to increase drug residence time, which in turn increases the time-concentration exposure product of therapeutic drug available to tumor.

Keywords: brain tumor, chemotherapy, drug delivery, hypothermia, interstitial fluid pressure

Received January 3, 2006; Accepted March 20, 2006


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
JCOHome page
L. L. Muldoon, C. Soussain, K. Jahnke, C. Johanson, T. Siegal, Q. R. Smith, W. A. Hall, K. Hynynen, P. D. Senter, D. M. Peereboom, et al.
Chemotherapy Delivery Issues in Central Nervous System Malignancy: A Reality Check
J. Clin. Oncol., June 1, 2007; 25(16): 2295 - 2305.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.